Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSimcere Pharma
Stock Code02096
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家從事藥品研發、生產和商業化的公司,目前主要從事仿製藥業務,專注腫瘤疾病、中樞神經系統疾病及自身免疫疾病等治療領域。
Listing Date2020-10-27
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)江蘇省南京市玄武區玄武大道699-18號
Business Address (Hong Kong)香港北角電氣道183號友邦廣場43樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitesimcere.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 13.70 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 13,700
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares260,569,000 shares
HK Public Offer Shares (Initial)26,058,000 shares (10.0%)
Public Offer Lots (Initial)26,058lots (Pool A13,029lots,Pool B13,029lots)
International Placing Shares (Initial)234,511,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,605,686,618 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share41.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,569,795,300

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 13,700
2 lots 2,000 HK$ 27,400
3 lots 3,000 HK$ 41,100
4 lots 4,000 HK$ 54,800
5 lots 5,000 HK$ 68,500
6 lots 6,000 HK$ 82,200
7 lots 7,000 HK$ 95,900
8 lots 8,000 HK$ 109,600
9 lots 9,000 HK$ 123,300
10 lots 10,000 HK$ 137,000
15 lots 15,000 HK$ 205,500
20 lots 20,000 HK$ 274,000
25 lots 25,000 HK$ 342,500
30 lots 30,000 HK$ 411,000
35 lots 35,000 HK$ 479,500
40 lots 40,000 HK$ 548,000
45 lots 45,000 HK$ 616,500
50 lots 50,000 HK$ 685,000
60 lots 60,000 HK$ 822,000
70 lots 70,000 HK$ 959,000
80 lots 80,000 HK$ 1,096,000
90 lots 90,000 HK$ 1,233,000
100 lots 100,000 HK$ 1,370,000
200 lots 200,000 HK$ 2,740,000
300 lots 300,000 HK$ 4,110,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
400 lots 400,000 HK$ 5,480,000
500 lots 500,000 HK$ 6,850,000
600 lots 600,000 HK$ 8,220,000
700 lots 700,000 HK$ 9,590,000
800 lots 800,000 HK$ 10,960,000
900 lots 900,000 HK$ 12,330,000
1,000 lots 1,000,000 HK$ 13,700,000
2,000 lots 2,000,000 HK$ 27,400,000
3,000 lots 3,000,000 HK$ 41,100,000
4,000 lots 4,000,000 HK$ 54,800,000
5,000 lots 5,000,000 HK$ 68,500,000
6,000 lots 6,000,000 HK$ 82,200,000
7,000 lots 7,000,000 HK$ 95,900,000
8,000 lots 8,000,000 HK$ 109,600,000
9,000 lots 9,000,000 HK$ 123,300,000
10,000 lots 10,000,000 HK$ 137,000,000
13,029 lots 13,029,000 HK$ 178,497,300

Stock Connect Inclusion Analysis

HK Market Cap HK$ 29.41B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 35,697,906,666
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status2019年盈利約人民幣1,003.6百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 10.98
First Day OpenHK$ 11.0
First Day Change-19.85%
First Day Volume125444000.0
First Day Turnover1369320000.0
Use of Proceeds
1、約60%(或2,035.4百萬港元)將分配予我們在戰略重點治療領域中選定的在研產品的持續研發; 2、約10%(或339.2百萬港元)將分配予加強我們的銷售及營銷能力; 3、約10%(或339.2百萬港元)將分配予我們于未來幾年投資醫藥或生物技術領域的公司,以拓寬我們的產品組合; 4、約10%(或339.2百萬港元)將分配予償還如下表所示的若干未償還銀行貸款; 5、約10%(或339.2百萬港元)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (4)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894 UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940
Joint Lead Managers (5)
Morgan Stanley Asia Limited CE AAD291 中国国际金融香港证券有限公司 CE AEN894 UBS Securities Hong Kong Limited CE BIN466 招银国际融资有限公司 CE AVM940 CNCB (Hong Kong) Capital Limited CE AEQ982

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Hillhouse Funds 387,504,500 HKD — 10.86% — 6 months 2021-04-27
2 Jericho Capital Master Fund L.P. 77,500,900 HKD — 2.17% — 6 months 2021-04-27
3 Lake Bleu Prime Healthcare Master Fund Limited 193,745,400 HKD — 5.43% — 6 months 2021-04-27
4 OrbiMed Funds 193,745,400 HKD — 5.43% — 6 months 2021-04-27
5 Sage Partners Master Fund 77,500,900 HKD — 2.17% — 6 months 2021-04-27
6 高新(香港)有限公司 310,003,600 HKD — 8.68% — 6 months 2021-04-27
7 红土创新国际有限公司 232,489,000 HKD — 6.51% — 6 months 2021-04-27

Directors & Management

PositionChinese nameEnglish Name
Chairman任晉生—
Company Secretary鮑軍、馮潔、麥寶文—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東任晉生先生及其一致行動人士(包括任用先生、李詩濛女士、任衛東先生、任真女士、彭素琴女士等)合共持有2,035,922,965股股份,緊隨全球發售完成後佔已發行股本約78.13%。
About this page

This page shows Simcere Pharma (02096) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect